UniSa - IRIS Institutional Research Information System

ERRO, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 17.637
NA - Nord America 9.849
EU - Europa 3.396
SA - Sud America 2.013
AF - Africa 208
OC - Oceania 67
Continente sconosciuto - Info sul continente non disponibili 7
Totale 33.177
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 11.479
US - Stati Uniti d'America 9.594
SG - Singapore 2.708
BR - Brasile 1.547
VN - Vietnam 1.117
CN - Cina 1.074
IT - Italia 847
RU - Federazione Russa 532
UA - Ucraina 369
IE - Irlanda 318
DE - Germania 312
TR - Turchia 309
FR - Francia 283
KR - Corea 239
SE - Svezia 195
AR - Argentina 180
GB - Regno Unito 151
IN - India 133
BD - Bangladesh 125
CA - Canada 122
ID - Indonesia 88
EC - Ecuador 77
FI - Finlandia 77
MX - Messico 77
JP - Giappone 76
CO - Colombia 66
IQ - Iraq 61
ZA - Sudafrica 57
NL - Olanda 54
PL - Polonia 52
EE - Estonia 37
AU - Australia 36
VE - Venezuela 36
ES - Italia 34
AT - Austria 32
MA - Marocco 32
PK - Pakistan 30
PY - Paraguay 30
NZ - Nuova Zelanda 28
CL - Cile 26
KE - Kenya 25
UZ - Uzbekistan 25
UY - Uruguay 20
EG - Egitto 19
DZ - Algeria 17
JO - Giordania 17
PE - Perù 17
CZ - Repubblica Ceca 16
SA - Arabia Saudita 16
PH - Filippine 14
TN - Tunisia 14
BO - Bolivia 12
LB - Libano 12
MY - Malesia 12
NP - Nepal 12
AE - Emirati Arabi Uniti 11
AL - Albania 11
LT - Lituania 11
AZ - Azerbaigian 10
DO - Repubblica Dominicana 10
JM - Giamaica 10
KZ - Kazakistan 10
IL - Israele 9
CH - Svizzera 8
PA - Panama 8
ET - Etiopia 7
GR - Grecia 7
IR - Iran 7
BE - Belgio 6
CI - Costa d'Avorio 6
CR - Costa Rica 6
KW - Kuwait 6
TH - Thailandia 6
HU - Ungheria 5
MD - Moldavia 5
OM - Oman 5
RS - Serbia 5
SN - Senegal 5
BG - Bulgaria 4
BH - Bahrain 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
XK - ???statistics.table.value.countryCode.XK??? 4
BY - Bielorussia 3
CY - Cipro 3
GE - Georgia 3
HR - Croazia 3
KG - Kirghizistan 3
MU - Mauritius 3
PR - Porto Rico 3
SO - Somalia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BF - Burkina Faso 2
BS - Bahamas 2
BW - Botswana 2
EU - Europa 2
HN - Honduras 2
KY - Cayman, isole 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 33.125
Salva come PNG Salva come JPEG
Città #
Hong Kong 11.465
Singapore 1.293
San Jose 1.223
Ann Arbor 1.219
Princeton 848
Dallas 674
Ashburn 580
Chandler 539
Wilmington 494
Jacksonville 431
Ho Chi Minh City 357
Council Bluffs 325
Dublin 309
The Dalles 276
Izmir 265
Lauterbourg 255
Beijing 227
Woodbridge 216
Hanoi 206
Houston 202
Salerno 187
Dong Ket 162
Moscow 155
Los Angeles 129
São Paulo 129
Andover 127
Pellezzano 121
Nanjing 115
New York 110
Naples 109
Santa Clara 80
Norwalk 70
Boardman 69
Tokyo 69
Fairfield 62
Frankfurt am Main 56
Munich 53
Rio de Janeiro 50
Nuremberg 48
Da Nang 47
Haiphong 46
Düsseldorf 44
Shenyang 44
Warsaw 43
Orem 42
Brasília 41
Pune 38
Tallinn 37
Hebei 36
Montreal 36
Curitiba 35
Nanchang 34
Changsha 33
Chicago 31
Rome 30
Belo Horizonte 29
Dearborn 29
Seoul 29
Columbus 28
Boston 27
Brooklyn 27
Johannesburg 27
Mestre 27
West Jordan 27
Jiaxing 26
Amsterdam 25
Baghdad 25
Guayaquil 25
London 25
San Diego 25
Stockholm 25
Tashkent 24
Denver 23
Nairobi 23
Porto Alegre 23
San Francisco 23
Seattle 23
Fortaleza 22
Milan 22
Phoenix 22
Quito 22
Redwood City 22
Guarulhos 21
Toronto 21
Washington 21
Atlanta 20
Turku 20
Salvador 19
Uberlândia 19
Thái Bình 18
Guangzhou 17
Amman 16
Buffalo 16
Hải Dương 16
Sydney 16
Cambridge 15
Biên Hòa 14
Bắc Ninh 14
Goiânia 14
Lecce 14
Totale 24.908
Salva come PNG Salva come JPEG
Nome #
Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables 1.191
Longitudinal change of energy expenditure, body composition and dietary habits in Progressive Supranuclear Palsy patients 959
Managing Device-Aided Treatments in Parkinson's Disease in Times of COVID-19 934
Sex Differences in Parkinson’s Disease: From Bench to Bedside 652
Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. 547
Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease 541
Gait Analysis in Progressive Supranuclear Palsy Phenotypes. 526
Combined regional T1w/T2w ratio and voxel-based morphometry in multiple system atrophy: A follow-up study 506
Psychometric properties of the Beck Depression Inventory-II in progressive supranuclear palsy 468
Quality of Life and Nonmotor Symptoms in Parkinson's Disease 461
White matter changes and the development of motor phenotypes in de novo Parkinson's Disease 450
Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry 450
Fist-Palm Test May Identify Mild Cognitive Impairment and Freezing of Gait in Parkinson's Disease: A Machine Learning Approach 399
Fist-Palm Test (FiPaT): a bedside motor tool to screen for global cognitive status 392
Energy expenditure, body composition and dietary habits in progressive supranuclear palsy 373
Non-invasive brain stimulation for dystonia: therapeutic implications 358
Apathy evaluation scale-informant version in progressive supranuclear palsy: Psychometric properties and clinical correlates 356
[¹²³I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. 335
Improving the Efficacy of Botulinum Toxin for Cervical Dystonia: A Scoping Review 333
Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy 315
Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study 294
Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. 270
Hypomorphic NOTCH3 mutation in an Italian family with CADASIL features 248
Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease 241
A Bayesian approach to Essential Tremor plus: A preliminary analysis of the TITAN cohort 237
Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects 221
Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients 214
Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study 210
Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy 197
Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale 183
ADCY5 mutations are another cause of benign hereditary chorea 181
Olfaction in Homozygous and Heterozygous SYNJ1 Arg258Gln Mutation Carriers 179
A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease 169
A window into the mind-brain-body interplay: Development of diagnostic, prognostic biomarkers, and rehabilitation strategies in functional motor disorders 167
Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study 164
Neuropsychological correlates of Pisa syndrome in patients with Parkinson's disease 163
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 158
Are granular osmiophilic material deposits an epiphenomenon in CADASIL? 150
Cognitive behavioural therapy and adjunctive physical activity for functional movement disorders (Conversion Disorder): A pilot, single-blinded, randomized study 150
Quitting smoking: An early non-motor feature of Parkinson's disease? 148
Increased bilirubin levels in de novo Parkinson's disease 148
Serum uric acid is associated with apathy in early, drug-naïve Parkinson’s disease 148
Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study 147
Abnormal eating behaviors in progressive supranuclear palsy. 145
Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy 145
Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. 142
Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease 142
Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease 140
Caffeine consumption and the 4-year progression of de novo Parkinson's disease 139
The Motor Syndrome of Parkinson's Disease 139
Spread of dystonia in patients with idiopathic adult-onset laryngeal dystonia 138
Machine learning can predict mild cognitive impairment in Parkinson's disease 135
Toward the premotor diagnosis of Parkinson's disease: Suggestions from a modelling study 134
Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? 133
Regional gray matter atrophy in patients with Parkinson disease and freezing of gait 130
Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease 130
The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. 128
Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy 128
The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: A 4-year longitudinal study 127
Gender and non motor fluctuations in Parkinson's disease: A prospective study 125
Cerebellar and brainstem functional abnormalities in patients with primary orthostatic tremor 125
Affective and cognitive theory of mind in patients with cervical dystonia with and without tremor 125
GBA-Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort 125
Malabsorption is uncommon in restless legs syndrome. 123
Early MRI findings in acquired hepatocerebral degeneration. 117
Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson’s disease 116
Orthostatic myoclonus associated with Caspr2 antibodies 116
The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy 115
MDS PSP criteria in real-life clinical setting: Motor and cognitive characterization of subtypes 115
Impact of COVID-19 on neurological patients attending a botulinum toxin service 115
Effects of gender on cognitive and behavioral manifestations in multiple system atrophy 114
On the relationship between side of onset and cognition in Parkinson disease 113
Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy 113
Comparing PIGD and Akinetic-Rigid subtyping of Parkinson Disease and their stability over time 113
Regional Gray Matter Atrophy in Patients with Parkinson Disease and Freezing of Gait. 113
A novel therapeutic approach for synucleinopathies 112
Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism 111
The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. 111
Bipolar Disorder and Parkinson’s Disease: A 123I-Ioflupane Dopamine Transporter SPECT Study 111
Presence and progression of non-motor symptoms in relation to uric acid inde novoParkinson's disease 110
Non-motor correlates of smoking habits in de novo Parkinson's disease 108
Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. 107
Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy 107
Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study. 106
Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease 106
Essential tremor plus rest tremor: current concepts and controversies 104
Midbrain MRI assessments in progressive supranuclear palsy subtypes 104
Uric acid relates to dopamine transporter availability in Parkinson's disease. 103
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. 103
A Screening Tool to Quickly Identify Movement Disorders in Patients with Inborn Errors of Metabolism 102
The "eye of the tiger" sign in pure akinesia with gait freezing. 102
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients 101
Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for? 99
Brittle response to levodopa as a marker of Parkinson’s disease phenotype characterized by heavy motor and non-motor burden 98
Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease 98
The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease 98
“Atypical” atypical parkinsonism: Critical appraisal of a cohort 97
Patients with Parkinson?s disease and scans with (predominant) ipsilateral dopaminergic deficit 96
Abnormal nociceptive processing occurs centrally and not peripherally in pain-free Parkinson disease patients: A study with laser-evoked potentials 96
Restless legs syndrome is a common feature of adult celiac disease 93
Totale 21.574
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.543
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.543
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021210 0 0 0 0 0 0 0 0 0 0 0 210
2021/20221.275 5 1 5 9 24 8 17 37 146 164 216 643
2022/20231.556 242 102 73 141 171 371 18 129 202 8 66 33
2023/20241.005 45 132 57 61 46 120 37 77 49 66 55 260
2024/20252.997 84 40 50 121 116 342 372 261 452 422 371 366
2025/202622.059 3.066 5.569 4.716 1.548 1.286 660 2.007 513 619 1.386 377 312
Totale 33.789